Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 Oct 2016 - 12 Oct 2016
12 Nov 2016 - 16 Nov 2016

Protein Block Stops Vascular Damage in Diabetes

By BiotechDaily International staff writers
Posted on 24 Jun 2013
Print article
A new study demonstrates that the inhibition of a protein activated when blood sugar is raised suppresses accelerated atherosclerosis in diabetic mice.

Researchers at Lund University (Sweden) conducted a study in Streptozotocin (STZ)-induced diabetic in mice to investigate whether Nuclear Factor of Activated T-Cells (NFAT) activation may be a link between diabetes and atherogenesis, by measuring blood monocytes, endothelial activation, and inflammatory markers in the aorta, and proinflammatory cytokines in plasma. The study was initiated following previous studies that showed that hyperglycemia activates the transcription factor NFAT in the arterial wall, inducing the expression of the pro-atherosclerotic protein osteopontin.

The study showed that NFAT activation resulted in 2.2 fold increase in aortic atherosclerosis and enhanced proinflammatory burden. Subsequent in vivo treatment with the NFAT blocker A-285222 for four weeks completely inhibited the diabetes-induced aggravation of atherosclerosis, while having no effect in nondiabetic mice. The STZ-treated mice also exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but these were unaffected by A-285222. In fact, the substance did not affect NFAT in any other cells or organs, ruling out systemic immunosuppression as the mechanism behind reduced atherosclerosis. The study was published in the June 3, 2013, issue of PLOS one.

“That is important. We don’t want to suppress the whole immune system. We also saw that the substance only has an effect when NFAT is active. The plaque formation was only stopped in diabetic mice and not in nondiabetic mice, which had normal blood sugar levels”, said lead author Anna Zetterqvist, MSc. “It appears that there are different mechanisms behind plaque formation caused by diabetes and not caused by diabetes.”

A wealth of epidemiologic evidence demonstrate that hyperglycemia promotes a widespread and aggressive form of atherosclerosis in the coronary arteries, lower extremities, and extracranial carotid arteries of diabetic patients, causing nearly 80% of all deaths and much of their disability. Both diabetes type 1 and type 2 are independent risk factors for myocardial infarction (MI), peripheral vascular disease (PVD), and stroke. In addition, recent studies also show a causal association between elevated glucose levels and increased carotid intima-media thickness, a marker of subclinical atherosclerosis.

Related Links:
Lund University



Print article

Channels

Drug Discovery

view channel
Image: Ginger is the source of a novel class of nanolipid transport vector (Photo courtesy of Georgia State University).

Ginger-Derived Doxorubicin-Loaded Nanovectors as Drug Delivery for Cancer Therapy

A novel type of nanoparticle drug transport system based on lipids isolated from ginger was used to deliver the toxic chemotherapeutic agent doxorubicin (Dox) to colon cancer cells with minimal damage... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.